Marinus Pharma CS (MRNS)

Jan 6, 2025, 6:06 PM EST - 3 months ago

MARINUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Marinus Pharmaceuticals, Inc. - MRNS

Dec 30, 2024, 7:00 AM EST - 3 months ago

Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.

Nov 12, 2024, 4:00 PM EST - 5 months ago

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Oct 24, 2024, 8:00 AM EDT - 5 months ago

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

Oct 17, 2024, 7:00 AM EDT - 6 months ago

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting

Oct 16, 2024, 1:17 PM EDT - 6 months ago

3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity

AMPX LODE

Oct 15, 2024, 4:00 PM EDT - 6 months ago

Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens

Oct 9, 2024, 7:00 AM EDT - 6 months ago

Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting

Oct 8, 2024, 4:04 PM EDT - 6 months ago

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Oct 7, 2024, 3:59 PM EDT - 6 months ago

Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?

Sep 20, 2024, 8:00 AM EDT - 6 months ago

Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day

Sep 12, 2024, 8:00 AM EDT - 7 months ago

Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024

Sep 10, 2024, 8:00 AM EDT - 7 months ago

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference

Aug 19, 2024, 8:00 AM EDT - 8 months ago

Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024

Aug 13, 2024, 2:17 PM EDT - 8 months ago

Marinus Pharmaceuticals, Inc. (MRNS) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:01 AM EDT - 8 months ago

Pacific Defense Announces US Army CMFF Program Team

MNMD

Aug 13, 2024, 7:00 AM EDT - 8 months ago

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 6:00 PM EDT - 8 months ago

Investors Are Invited To Participate In The Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm

Aug 6, 2024, 5:45 PM EDT - 8 months ago

MRNS Investors Have Opportunity To Join Marinus Pharmaceuticals Inc Fraud Investigation With The Schall Law Firm

Aug 5, 2024, 10:30 AM EDT - 8 months ago

MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

Jul 30, 2024, 9:15 AM EDT - 8 months ago

Marinus Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm Which Encourages Affected Investors To Initiate Discussions

Jul 30, 2024, 8:00 AM EDT - 8 months ago

Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024

Jul 29, 2024, 8:36 AM EDT - 8 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Investors to Contact the Firm Before August 5, 2024

Jul 26, 2024, 5:30 PM EDT - 8 months ago

Marinus Pharmaceuticals Inc Is Being Probed By The Schall Law Firm Which Motivates Affected Investors To Begin Discussions

Jul 25, 2024, 9:55 AM EDT - 9 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus

Jul 19, 2024, 9:50 AM EDT - 9 months ago

Faruqi & Faruqi LLP Reminds Shareholders of a Lead Plaintiff Deadline on August 5, 2024 in Marinus Lawsuit

Jul 18, 2024, 6:15 PM EDT - 9 months ago

Marinus Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm Which Urges Impacted Investors To Initiate Conversations

Jul 18, 2024, 7:00 AM EDT - 9 months ago

Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder

Jul 17, 2024, 7:00 PM EDT - 9 months ago

The Schall Law Firm Starts An Investigation Into Marinus Pharmaceuticals Inc And Encourages Affected Investors To Begin Dialogue

Jul 16, 2024, 3:45 PM EDT - 9 months ago

The Schall Law Firm Commences A Probe Into Marinus Pharmaceuticals Inc And Urges Impacted Investors To Initiate Discussion

Jul 13, 2024, 5:00 PM EDT - 9 months ago

The Schall Law Firm Initiates An Inquiry Into Marinus Pharmaceuticals Inc And Urges Impacted Investors To Start Conversation

Jul 11, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Begins A Probe Into Marinus Pharmaceuticals Inc And Urges Impacted Investors To Initiate Communication

Jul 9, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Starts An Investigation Into Marinus Pharmaceuticals Inc And Calls On Affected Investors To Make Contact

Jul 8, 2024, 2:30 PM EDT - 9 months ago

The Schall Law Firm Begins A Probe Into Marinus Pharmaceuticals Inc And Encourages Impacted Investors To Get In Touch

Jul 7, 2024, 11:00 AM EDT - 9 months ago

An Inquiry Into Marinus Pharmaceuticals Inc Is Launched By The Schall Law Firm, Encouraging Impacted Investors To Commence Dialogue